Ratings by Barclays (Eliana Merle)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/6/2026 | Regeneron Pharma | REGN | New Coverage | Overweight (N/A) |
787.50 (759.86) |
-3.51% | Details | |
| 3/3/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2026 | Gossamer Bio Inc. | GOSS | Downgrade | Underweight (Overweight) |
2.13 (0.50) |
-76.53% | Details | |
| 2/23/2026 | PTC Therapeutics | PTCT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/28/2026 | Tyra Biosciences | TYRA | New Coverage | Overweight (N/A) |
30.17 (35.04) |
16.14% | Details | |
| 1/28/2026 | MBX Biosciences Inc | MBX | New Coverage | Overweight (N/A) |
36.60 (30.55) |
-16.53% | Details | |
| 1/28/2026 | Regenxbio Inc. | RGNX | New Coverage | Overweight (N/A) |
13.85 (8.65) |
-37.55% | Details | |
| 1/28/2026 | uniQure BV | QURE | New Coverage | Equalweight (N/A) |
25.27 (14.27) |
-43.53% | Details | |
| 1/28/2026 | Sarepta Therapeutics | SRPT | New Coverage | Equalweight (N/A) |
22.80 (16.71) |
-26.71% | Details | |
| 1/28/2026 | Moderna | MRNA | New Coverage | Equalweight (N/A) |
47.99 (52.52) |
9.44% | Details | |
| 1/28/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 1/28/2026 | Sagimet Biosciences Inc | SGMT | New Coverage | Equalweight (N/A) |
6.03 (5.41) |
-10.28% | Details | |
| 1/28/2026 | Kymera Therapeutics | KYMR | New Coverage | Overweight (N/A) |
71.06 (83.49) |
17.49% | Details | |
| 1/28/2026 | BridgeBio Pharma | BBIO | New Coverage | Overweight (N/A) |
77.81 (65.36) |
-16% | Details | |
| 1/28/2026 | Ionis Pharmaceuticals | IONS | New Coverage | Overweight (N/A) |
81.00 (74.04) |
-8.59% | Details | |
| 1/28/2026 | Apellis Pharmaceuticals | APLS | New Coverage | Equalweight (N/A) |
21.99 (20.07) |
-8.73% | Details | |
| 1/28/2026 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Overweight (N/A) |
56.78 (61.12) |
7.64% | Details | |
| 1/28/2026 | 4D Molecular Therapeutics | FDMT | New Coverage | Overweight (N/A) |
7.97 (8.48) |
6.4% | Details | |
| 1/28/2026 | Gossamer Bio Inc. | GOSS | New Coverage | Overweight (N/A) |
2.66 (2.13) |
-19.92% | Details | |
| 1/28/2026 | Ascendis Pharma | ASND | New Coverage | Overweight (N/A) |
233.65 (240.65) |
3% | Details | |
| 1/28/2026 | Alnylam Pharmaceuticals | ALNY | New Coverage | Overweight (N/A) |
361.35 (320.66) |
-11.26% | Details | |
| 1/28/2026 | Insmed | INSM | New Coverage | Overweight (N/A) |
159.72 (140.13) |
-12.27% | Details | |
| 1/28/2026 | Inventiva SA | IVA | New Coverage | Overweight (N/A) |
7.07 (6.13) |
-13.3% | Details | |
| 1/28/2026 | Madrigal Pharmaceuticals | MDGL | New Coverage | Overweight (N/A) |
499.17 (432.83) |
-13.29% | Details | |
| 1/28/2026 | Altimmune | ALT | New Coverage | Overweight (N/A) |
5.66 (3.54) |
-37.46% | Details | |
| 1/28/2026 | PTC Therapeutics | PTCT | New Coverage | Overweight (N/A) |
76.23 (62.82) |
-17.59% | Details | |
| 1/28/2026 | Vertex | VRTX | New Coverage | Overweight (N/A) |
476.84 (456.69) |
-4.23% | Details |
